Trial Profile
Phase III Trial of Neoadjuvant Recombinant Human Endostatin, Docetaxel and Epirubicin as First-Line Therapy in Patients With Breast Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Feb 2019
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Endostatin (Primary) ; Epirubicin (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 15 May 2018 Status changed from recruiting to completed,as reported in an article published in the International Journal of Cancer
- 06 Dec 2011 New trial record